Medical Condition News

RSS

Findings could lead to treatments for blood disorders associated with iron deficiencies and overloads

A UCLA research team has discovered a new hormone called erythroferrone, which regulates the iron supply needed for red blood-cell production.

2 Jun 2014

BRCA2 gene doubles lung cancer risk among smokers

Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals.

2 Jun 2014

Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Myriad Genetics, Inc. today presented several clinical studies on the Myriad myRisk- Hereditary Cancer test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

2 Jun 2014

Pivotal clinical validation study of Myriad myPath Melanoma test presented at ASCO 2014

Myriad Genetics, Inc. today presented results from a pivotal clinical validation study of the Myriad myPath- Melanoma test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Ill.

2 Jun 2014

Volatile organic compounds in exhaled breath show presence and stage of lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.

2 Jun 2014

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL).

2 Jun 2014

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics, the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors.

From Quest Diagnostics 2 Jun 2014

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report.

31 May 2014

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β).

31 May 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.

31 May 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled "Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next-generation sequencing (NGS)" (Abstract #6072) at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.

31 May 2014

New software tool helps identify genetic mutations linked to increased risk for cancer

Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person's increased risk for developing common, complex diseases, such as cancer.

31 May 2014

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap.

31 May 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

Fatigue is a debilitating problem for cancer patients undergoing treatment; however, it also poses a huge detriment after treatment and can significantly affect quality of life.

31 May 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Medical Condition News

Findings could lead to treatments for blood disorders associated with iron deficiencies and overloads

BRCA2 gene doubles lung cancer risk among smokers

Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Pivotal clinical validation study of Myriad myPath Melanoma test presented at ASCO 2014

Volatile organic compounds in exhaled breath show presence and stage of lung cancer

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Amgen presents extended analysis of PEAK study data at ASCO

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New software tool helps identify genetic mutations linked to increased risk for cancer

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News